PACT Pharma, Inc.

PACT Pharma, Inc. is a biotechnology company focused on developing personalized cancer therapies using advanced cell therapy technology to enhance treatment efficacy for patients. PACT Pharma, Inc. specializes in personalized cell therapy for cancer treatment.

Founded in 2016 and headquartered in South San Francisco, US, the company has completed a total of 3 deals, with its most recent funding round, Series C, occurring on September 30, 2022. Led by Vida Ventures, this round raised USD 45. 37 mn, bringing the total amount raised to USD 45. 37 mn and a current valuation of USD 292.

96 mn. The CEO is Scott Garland, whose experience includes roles at leading biotech firms. PACT Pharma, Inc. offers innovative therapeutic solutions centered on personalized cancer treatment through advanced cell therapy technology.

Their core services include the development of customized T-cell therapies tailored to target specific cancer cells, improving patient outcomes. The company’s offerings are designed to enhance clinical efficacy and patient engagement in cancer care, targeting mid to large-sized healthcare enterprises. Their solutions have been systematically enhanced through ongoing clinical trials and user feedback, focusing on significant markets across North America and Europe. PACT Pharma generates revenue through its proprietary cancer therapies, which are primarily offered on a subscription basis to healthcare institutions.

Clients engage through licensing agreements for personalized treatment protocols. The pricing structure is designed to accommodate various healthcare providers, offering scalable solutions that meet diverse patient needs. Strategic partnerships further bolster revenue opportunities, allowing for bundled therapy offerings that cater to a broad range of oncology practices. As part of its growth strategy, PACT Pharma is actively developing new personalized therapies aimed at broader cancer types, with planned launches in 2023.

The company aims to expand its market footprint into Europe and Asia by 2024, leveraging recent funding to enhance its R&D capabilities. The recent acquisition agreement with AmplifyBio in September 2022 is expected to support these initiatives, allowing PACT Pharma to tap into additional resources for product development and market expansion.